Radiation treatment for patients with intermediate-risk prostate cancer

David E. Greene, Jyoti S. Mayadev, Richard K Valicenti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.

Original languageEnglish (US)
Pages (from-to)113-124
Number of pages12
JournalTherapeutic Advances in Urology
Volume4
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Prostatic Neoplasms
Radiation
Combined Modality Therapy
Radiation Oncology
Standard of Care
Radiotherapy
Therapeutics

Keywords

  • androgen deprivation
  • brachytherapy
  • dose escalation
  • external beam
  • intermediate risk
  • outcomes
  • prostate cancer
  • radiation
  • review

ASJC Scopus subject areas

  • Urology

Cite this

Radiation treatment for patients with intermediate-risk prostate cancer. / Greene, David E.; Mayadev, Jyoti S.; Valicenti, Richard K.

In: Therapeutic Advances in Urology, Vol. 4, No. 3, 06.2012, p. 113-124.

Research output: Contribution to journalArticle

@article{076124c6ae154e78b3ac58f01625708e,
title = "Radiation treatment for patients with intermediate-risk prostate cancer",
abstract = "Around 70{\%} of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.",
keywords = "androgen deprivation, brachytherapy, dose escalation, external beam, intermediate risk, outcomes, prostate cancer, radiation, review",
author = "Greene, {David E.} and Mayadev, {Jyoti S.} and Valicenti, {Richard K}",
year = "2012",
month = "6",
doi = "10.1177/1756287212442977",
language = "English (US)",
volume = "4",
pages = "113--124",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Radiation treatment for patients with intermediate-risk prostate cancer

AU - Greene, David E.

AU - Mayadev, Jyoti S.

AU - Valicenti, Richard K

PY - 2012/6

Y1 - 2012/6

N2 - Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.

AB - Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.

KW - androgen deprivation

KW - brachytherapy

KW - dose escalation

KW - external beam

KW - intermediate risk

KW - outcomes

KW - prostate cancer

KW - radiation

KW - review

UR - http://www.scopus.com/inward/record.url?scp=84861864345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861864345&partnerID=8YFLogxK

U2 - 10.1177/1756287212442977

DO - 10.1177/1756287212442977

M3 - Article

C2 - 22654963

AN - SCOPUS:84861864345

VL - 4

SP - 113

EP - 124

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 3

ER -